Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab with neoadjuvant chemoradiation followed by surgery for operable esophageal cancer
2008-008209-22Phase 2Completed
- Sponsor
- Academic Medical Center
- Start
- Dec 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, carboplatin and paclitaxel in esophageal cancer and esophagogastric junction cancer, sponsored by Academic Medical Center. Primary endpoint: Percentage of pathologic complete responses. Started Dec 2008; status: completed.
02
Drugs
panitumumabcarboplatinpaclitaxel
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on 2008-008209-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008209-22.